2023 - Research.com Biology and Biochemistry in Switzerland Leader Award
The scientist’s investigation covers issues in Antibody, Cancer research, Immunology, Molecular biology and CD20. His studies deal with areas such as Computational biology, Antigen and Anti vegf as well as Antibody. His work deals with themes such as T cell, Proto-Oncogene Proteins c-mdm2, Mdm2 and Cancer immunotherapy, which intersect with Cancer research.
His Molecular biology study incorporates themes from Protein structure, Biochemistry, Antigen binding and Bivalent. The various areas that Christian Klein examines in his CD20 study include Monoclonal antibody, Antibody-dependent cell-mediated cytotoxicity and Rituximab. His research integrates issues of Cell cycle, Nutlin and Growth inhibition, Cell growth in his study of Nuclear protein.
His scientific interests lie mostly in Antibody, Cancer research, Immunology, CD20 and T cell. His Antibody research incorporates themes from Molecular biology, Receptor and Antigen. His Cancer research research focuses on Cancer and how it connects with Combination therapy.
He specializes in Immunology, namely IL-2 receptor. His study in CD20 is interdisciplinary in nature, drawing from both Pharmacology, Antibody-dependent cell-mediated cytotoxicity, B cell and Rituximab. His research in T cell intersects with topics in Carcinoembryonic antigen, Tumor microenvironment, CD3, CD8 and Tumor antigen.
Christian Klein mainly investigates Cancer research, Antibody, T cell, Obinutuzumab and Receptor. His research on Cancer research also deals with topics like
Christian Klein interconnects Cytokine, B cell, Tumor antigen and Antigen in the investigation of issues within T cell. His study focuses on the intersection of Receptor and fields such as Cell biology with connections in the field of Chimeric antigen receptor. His biological study spans a wide range of topics, including Leukemia and Diffuse large B-cell lymphoma.
His primary areas of investigation include Cancer research, Antibody, T cell, Obinutuzumab and Immunotherapy. The study incorporates disciplines such as Cytotoxic T cell, Granzyme B, CD8, Receptor and In vivo in addition to Cancer research. Christian Klein has included themes like Cell biology, Chimeric antigen receptor and Cytotoxicity in his Antibody study.
In his study, which falls under the umbrella issue of Chimeric antigen receptor, CD20 is strongly linked to Cancer cell. His T cell study combines topics from a wide range of disciplines, such as Antigen and Cancer immunotherapy. His Obinutuzumab research is multidisciplinary, incorporating elements of Venetoclax and Monoclonal.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.
Lyubomir T. Vassilev;Binh T. Vu;Bradford Graves;Daisy Carvajal.
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity
Ekkehard Mössner;Peter Brünker;Samuel Moser;Ursula Püntener.
Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker.
Flavio Solca;Goeran Dahl;Andreas Zoephel;Gerd Bader.
Journal of Pharmacology and Experimental Therapeutics (2012)
A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade
Daniela S. Thommen;Daniela S. Thommen;Viktor H. Koelzer;Petra Herzig;Andreas Roller.
Nature Medicine (2018)
Bivalent, bispecific antibodies
Christian Klein;Wolfgang Schaefer.
Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling
Moritz Felcht;Robert Luck;Alexander Schering;Philipp Seidel.
Journal of Clinical Investigation (2012)
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies
Wolfgang Schaefer;Jörg T. Regula;Monika Bähner;Jürgen Schanzer.
Proceedings of the National Academy of Sciences of the United States of America (2011)
Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53.
Raphael Stoll;Christian Renner;Silke Hansen;Stefan Palme.
p53 contains large unstructured regions in its native state.
Stefan Bell;Christian Klein;Lin Müller;Silke Hansen.
Journal of Molecular Biology (2002)
Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties
Christian Klein;Alfred Lammens;Wolfgang Schäfer;Guy Georges.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: